What is Immuno Technologies?
Immuno Technologies, Inc. (ITi) is a Memphis, TN-based biotechnology firm dedicated to developing innovative vaccines and diagnostic assays for challenging diseases such as Lyme disease and leptospirosis. The company's pipeline includes a promising intranasal vaccine for Lyme disease currently in active development. ITi is actively seeking strategic partnerships to facilitate the commercialization of its proprietary biologics, building upon its history of securing non-dilutive Small Business Innovation Research (SBIR) grants since 2014. Their focus on disease prevention and diagnostics positions them as a key player in the public health sector.
How much funding has Immuno Technologies raised?
Immuno Technologies has raised a total of $1M across 1 funding round:
Grant
$1M
Grant (2014): $1M, investors not publicly disclosed
What's next for Immuno Technologies?
With a foundation built on substantial enterprise-level capital and strategic investment, Immuno Technologies is poised for significant growth. The company's focus on advancing its preclinical research, particularly the intranasal Lyme disease vaccine, suggests a strategic push towards clinical trials and eventual market entry. Future endeavors will likely involve forging robust commercialization partnerships and potentially further financing rounds to support scaling manufacturing and distribution efforts. The company's commitment to addressing unmet needs in infectious disease prevention and diagnostics indicates a strong trajectory for impact and market penetration.
See full Immuno Technologies company page
